Normal 0 false false false MicrosoftInternetExplorer4 Dynavax Technologies Corp. (NASDAQ: DVAX) shares slumped 2.5% to $4.64. Late Thursday, the company said that the U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee voted eight to five with one abstention that there was insufficient data to adequately support the safety of the firm’s hepatitis B vaccine product HEPLISAV. Share volume was 40,000 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman"; mso-ansi-language:#0400; mso-fareast-language:#0400; mso-bidi-language:#0400;}